XM does not provide services to residents of the United States of America.
A
A

AbbVie

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Vraylar sales growth seen slowing in 2025, says Richter CEO

Vraylar sales growth seen slowing in 2025, says Richter CEO Richter's CEO expects slower growth in Vraylar sales Core business revenue growth surpasses Vraylar, CEO says Richter faces challenges in Russian operations due to sanctions By Anita Komuves BUDAPEST, Dec 12 (Reuters) - Hungarian pharmaceutical company Richter GDRB.BU expects a slowdown in sales growth for its flagship product, Vraylar, next year while supply chain disruptions continue to pose challenges, CEO Gabor Orban told Reuters on
A

Contact lens maker Bausch + Lomb says it is exploring sale

UPDATE 2-Contact lens maker Bausch + Lomb says it is exploring sale Adds share performance in paragraph 4, background in paragraph 6-9 Dec 12 (Reuters) - Bausch + Lomb BLCO.TO is exploring a potential sale among other o ptions , it said on Thursday, in a move that would help Canadian parent Bausch Health BHC.TO exit the eye-care company. Bausch + Lomb also said its statement was in response to a request from the Canadian Investment Regulatory Organization (CIRO) after a series of media reports o
A
B

AnaptysBio to abandon eczema drug development after mid-stage trial failure

UPDATE 2-AnaptysBio to abandon eczema drug development after mid-stage trial failure Updates shares in paragraph 1, adds details on disease and background in paragraphs 4-6 Dec 11 (Reuters) - AnaptysBio ANAB.O will end the development of its experimental drug to treat eczema as the treatment failed to meet the goals of a mid-stage trial, the company said on Wednesday, dragging its shares nearly 40% lower.
A
P
R
S

Health Rounds: New combination treatments promising for blood cancers

Health Rounds: New combination treatments promising for blood cancers Health Rounds is published on Tuesdays and Thursdays. Think your friend or colleague should know about us? Forward this newsletter to them. They can also subscribe here . By Nancy Lapid Dec 10 (Reuters) - Hello Health Rounds Readers! Today we cover a trio of studies on combination therapies presented at one of the year's most important meetings on blood disorders and cancers, the American Society of Hematology meeting in San D
A
B
R

Revance agrees to lower take-private offer by Crown Labs

UPDATE 2-Revance agrees to lower take-private offer by Crown Labs Adds details on deal throughout, background in paragraphs 2, 4-7 Dec 9 (Reuters) - Crown Laboratories would buy the anti-wrinkle injection maker Revance Therapeutics RVNC.O at a roughly 50% lower price compared to an original agreement signed in August, the companies said on Monday, sending the latter's stock tumbling 20%.
A

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.